Belimumab Aids Anti-dsDNA+, Hypocomplementemic Lupus

Share this content:
Belimumab Aids Anti-dsDNA+, Hypocomplementemic Lupus
Belimumab Aids Anti-dsDNA+, Hypocomplementemic Lupus

MONDAY, April 23, 2018 (HealthDay News) -- Weekly belimumab is associated with greater benefit than placebo for patients with hypocomplementemic/anti-double stranded (ds)DNA-positive systemic lupus erythematosus (SLE), according to a study published online April 18 in Arthritis & Rheumatology.

Andrea Doria, M.D., from the University of Padua in Italy, and colleagues examined the efficacy and safety of belimumab in a subset of patients with SLE who were hypocomplementemic (C3 and/or C4) and anti-dsDNA-positive at baseline (356 of 836 patients). Patients were randomized to weekly subcutaneous (SC) belimumab or placebo (248 and 108 patients, respectively), plus standard SLE therapy for 52 weeks. SLE Responder Index (SRI4) at week 52 was assessed as the primary end point.

The researchers found that the belimumab group contained more SIR4 responders than the placebo group (64.6 versus 47.2 percent; P = 0.0014), and they had lower incidence of severe SLE Flare Index flare (14.1 versus 31.5 percent). Furthermore, more patients in the belimumab group were able to reduce corticosteroid use by ≥25 percent to ≤7.5 mg/day during weeks 40 to 52 (20.7 versus 11.4 percent; P = 0.0844). The treatment groups had similar adverse events.

"In patients with hypocomplementemic/anti-dsDNA-positive SLE, weekly belimumab 200 mg SC significantly improved SRI4 response, decreased severe flare incidence, and reduced corticosteroid use, versus placebo," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, which manufacturers belimumab and funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Some California Mosquitoes Can Carry Zika Virus

Some California Mosquitoes Can Carry Zika Virus

Aedes aegypti mosquitoes found to transmit Zika virus

Periodontal Inflammation a Risk With Tongue Piercing

Periodontal Inflammation a Risk With Tongue Piercing

And, two young females with tongue piercings have deep lingual infrabony lesions, periodontitis

Risk of OD Highest for First Days of Opioid  Benzodiazepine Use

Risk of OD Highest for First Days of ...

Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use

is free, fast, and customized just for you!




Already a member?

Sign In Now »